Andrew Huberman· PhD
whereas ipamorelin or ibutamoren, which is also known as MK-677, those two are in the class of ghrelin agonist. So they're more like they hit the receptor that ghrelin does whereas the other ones hit the GHRH receptor.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
whereas ipamorelin or ibutamoren, which is also known as MK-677, those two are in the class of ghrelin agonist. So they're more like they hit the receptor that ghrelin does whereas the other ones hit the GHRH receptor.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
On Ipamorelin, it copies a chemical called ghrelin, the one that makes you hungry. On its own it gives you a quick burst of growth hormone that fades fast. It does not keep your longer acting growth signal (called IGF-1) up.
On Ipamorelin, it copies a chemical called ghrelin, the one that makes you hungry. On its own it gives you a quick burst of growth hormone that fades fast. It does not keep your longer acting growth signal (called IGF-1) up.
So even if you are stimulating the ghrein receptor, the effects on appetite are quite different. So for ipmrillin for example despite the fact that that's the receptor it's working through and it is a ghrein receptor agonist it does not influence hunger to even any reasonable magnitude within striking distance of MK677 ibutamoran